Bal Pharma

Price chart

Previous close

₹82.52

Open

₹83.50

Day high

₹83.50

Day low

₹82.00

Listed on NSE since 8 May 2006.

Market value

₹129.83 Cr

P/E (trailing)

17.96

EPS (trailing)

₹4.54

Price to book

1.58

Dividend yield

1.47%

Debt to equity

1.94

Profit margin

2.2%

Beta

0.57

Volume today

3,300

Average volume

60,799

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Bal Pharma’s results filed with NSE, consolidated (the whole group). Net profit is the share of Bal Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Bal Pharma’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Bengaluru

Employees

939

Company website · Profile: Yahoo Finance

No headlines name Bal Pharma in the last day or two.

• Dividend - Rs 1.20 Per Share

  Dividend · ex-date 17 September 2026

• Dividend - Rs 1.20 Per Share

  Dividend · ex-date 18 September 2025

• Annual General Me0etingdividend - Rs 1.2 Per Share

  Dividend · ex-date 17 September 2024

• Annual General Meeting/Dividend - Re 1 Per Share

  Dividend · ex-date 18 September 2023

• Annual General Meetingdividend - Re 1 Per Share

  Dividend · ex-date 13 September 2022

• Annual General Meeting/Dividend - Re 1 Per Share

  Dividend · ex-date 16 September 2021

• Annual General Meeting

  Action · ex-date 17 September 2020

• Annual General Meeting/Dividend - Re 1 Per Share

  Dividend · ex-date 17 September 2019

Source: NSE. Latest first, 8 of 20.